Missing chromosome predicts brain tumor patients' response to treatment

Feb 18, 2008

People with a highly aggressive type of brain tumor who are missing a specific chromosome live longer and respond better to the chemotherapy drug temozolomide than people without this genetic abnormality, according to research published in the February 19, 2008, issue of Neurology, the medical journal of the American Academy of Neurology. Gliomatosis cerebri is a rare type of brain tumor that is difficult to diagnosis, cannot be operated on, and has an extremely variable prognosis.

“Our findings will help doctors better predict who will respond best to temozolomide, which has recently been proposed as a new treatment for gliomatosis cerebri,” said Marc Sanson, MD, PhD, with INSERM, the French government health agency, in Paris, France. “Before now, we weren’t sure which factors influenced how well a person with this type of brain tumor would respond to the treatment.”

For the study, 25 people with gliomatosis cerebri underwent genetic testing and received monthly treatments of temozolomide for up to two years.

The study found nearly all of the participants who were missing chromosome 1p and 19q had a higher response rate to temozolomide and lived longer.

“Eighty-eight percent of those people with this genetic signature responded well to temozolomide compared to only 25 percent of those people without the genetic abnormality,” said Sanson. “In addition, those without 1p and 19q survived an average five and half years compared to only 15 months for the group with intact 1p and 19q. Those missing 1p and 19q also had more months without the tumor further progressing. Therefore, temozolomide is now our first choice of treatment for patients with gliomatosis cerebri, especially when missing chromosomes 1p and 19q.”

Source: American Academy of Neurology

Explore further: The impact of bacteria in our guts

add to favorites email to friend print save as pdf

Related Stories

Chemotherapy drug shrinks brain tumors

May 21, 2007

Cancerous brain tumors appear to respond favorably to the drug temozolomide when used as primary chemotherapy after surgery, and the treatment appears to work best in people missing a certain gene, according to a study published ...

Recommended for you

The impact of bacteria in our guts

Aug 22, 2014

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

Aug 22, 2014

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

Aug 22, 2014

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0